Gestalt Diagnostics to Participate in Digital Pathology Connectathon
Gestalt Diagnostics is pleased to announce our participation in the Digital Pathology Connectathon during the Pathology Visions 2018 Conference. The Digital Pathology Association and DICOM WG 26 collaborate on this initiative along with key vendor participants, such as Gestalt.
The Connectathon will showcase the use of the DICOM Standard to achieve interoperability of the Whole Slide
Imaging between different participants’ equipment and software. Participating vendors will also demonstrate
this interoperability in their booth on the exhibit hall floor. “The reuse of DICOM-based best-of-breed and
existing intra-enterprise and cross-enterprise infrastructure for use in clinical, research, education and
telepathology application will be emphasized”, according to DICOM WG 26.
Gestalt will be highlighting our PACs offering which espouses our advocacy around open standards while
promoting advanced technology towards reliable patient care. “Gestalt will be demonstrating our PACs ability
to accept DICOM artifacts as well as comply with DICOMWeb standards such as WADO-RS, QIDO-RS and
WADO-URI during the connectathon. These all represent a necessary step in standardizing interoperability in
Digital Pathology”, says Roopam Kakoti, Director of Development, Gestalt Diagnostics.
Lisa-Jean Clifford, Gestalt Diagnostics COO & Chief Strategy Officer states, “We are excited to be participating
in this interoperative, joint initiative. At Gestalt we pride ourselves on being able to work in a universally
compatible way with other platforms, vendors and software applications, and utilizing an industry standard
ensures that healthcare facilities will have access to the best solutions available on the market. They will not
be forced to choose hardware and software developed by one vendor to have access to an integrated
solution. Laboratories, and their IT departments, will be able to be confident in selecting the best products
from a variety of vendors to achieve their specific goals and objectives.”
Be sure to visit us in Booth #107 during the conference being held November 4-6, 2018 in San Diego, CA.
About Gestalt Diagnostics
Gestalt Diagnostics is a private, profit-driven software company who has developed PathFlow, an enterprise
software platform specifically designed to bring the benefits of digital workflow to pathologists and
pathology laboratories. This product was originally developed, by what is now Gestalt’s team, to
support a fully digital reading platform for radiology. The radiology platform is used in leading
hospitals across the United States and supports more than 13 million studies annually. Gestalt has
expanded and redesigned this proven, robust solution to work in the laboratory space – engineered
for the unique needs and workflow of pathologists.
July 2025 Digipath Dispatch – Industry news, digital pathology insights, product updates, and events from Gestalt Diagnostics.
Gestalt’s PathFlow and PathCloud unify pathology workflows, enabling seamless, multi-vendor integration for faster, accurate diagnoses.
Discover why digital pathology is gaining momentum and how it’s shaping diagnostics, improving workflows, and addressing workforce challenges in healthcare.
Discover how Lisa-Jean Clifford is helping shape the future of AI in pathology through a new framework designed for safe, scalable clinical integration.
Spokane, Washington, June 17, 2025 – Gestalt, a leading provider of AI-powered digital pathology solutions, today announced the addition of Dr. Renuka Kulkarni, MD, as Chief Medical Officer (CMO). A physician scientist with over 20 years of experience in surgical and digital pathology, Dr. Kulkarni will join the team in guiding Gestalt’s product direction and clinical usability. Dr. Kulkarni brings a rare blend of diagnostic precision and scientific innovation to the organization. Her expertise in breast pathology, immunomarkers, machine learning, and image analysis strengthens Gestalt’s mission to revolutionize diagnostic workflows and clinical decision-making through technology. “Renuka’s addition signals our deepening investment in the future of pathology,” said Lisa-Jean Clifford, President of Gestalt Diagnostics. “Her leadership and experience at the intersection of clinical insight, AI, and enterprise lab operations will ensure our solutions continue to serve both pathologists and the patients they care for.” Before joining Gestalt, Dr. Kulkarni played a pivotal role in developing one of the earliest digital pathology programs at a leading full-service reference laboratory. Her extensive hands-on experience with Gestalt’s solutions, as a customer and direct user for four years, along with image analysis platforms, and combined with her understanding of real-world lab operations, positions her to help bridge the clinical and commercial realms—ensuring the scalability and impact of Gestalt’s solutions. As CMO, Dr. Kulkarni will help shape the development of next-generation diagnostic tools, supporting Gestalt’s mission to enhance diagnostic accuracy, efficiency, and interoperability across health systems worldwide. “I’m honored to join Gestalt at such a transformative moment in digital pathology,” said Dr. Kulkarni. “Together, we have the opportunity to shape solutions that truly serve pathologists and ultimately improve outcomes for patients everywhere.” About Gestalt Gestalt Diagnostics is a Spokane-based company dedicated to revolutionizing pathology through digital solutions. Founded in 2017, Gestalt provides advanced technology, proven digital expertise, and artificial intelligence to enable pathologists to diagnose diseases faster and more efficiently. The company's PathFlow platform is at the forefront of digital pathology innovation, offering significant improvements in diagnostic accuracy and workflow efficiency. To learn more, visit www.gestaltdiagnostics.com and follow @Gestalt on LinkedIn
Date : Wednesday, May 21, 2025 Time : 1:45 PM Location : Auditorium 1, Marriott Eagle Crest Resort (Ann Arbor, Michigan) Session Title : The Long-Term Advantages of Digital Pathology are Only Realized Through True Interoperability We’re proud to announce that Lisa-Jean Clifford , COO & Chief Strategy Officer at Gestalt Diagnostics, and Sumie Edwards (ARUP) will take the stage at the 2025 Pathology Informatics Summit to share key insights into the critical role of interoperability in digital pathology. In this featured session, Lisa-Jean will explore: Why interoperability is the linchpin for scalable, future-ready digital pathology programs How health systems can unlock long-term value and efficiency through seamless integration Real-world considerations for IT infrastructure, workflow design, and cross-platform compatibility Her session will offer a strategic lens into how institutions can achieve meaningful digital transformation, not just implement new tools. About the PI Summit : The Pathology Informatics Summit is a premier annual event for professionals at the forefront of digital pathology, laboratory medicine, AI, and healthcare data innovation. It brings together leading physicians, researchers, and informaticists to discuss the rapidly evolving field. Mark your calendar for May 21 at 1:45 PM to hear Lisa-Jean share her vision for a more connected and impactful future in pathology.
Date : Thursday, May 22, 2025 Time : 9:00 AM – 12:00 PM Location : Auditorium 1, Marriott Eagle Crest Resort (Ann Arbor, Michigan) Panel Title : API Focus Session: Expert Panel on LDT Regulation Overhaul and Data Challenges in Pathology Informatics Join Lisa-Jean Clifford , COO & Chief Strategy Officer at Gestalt Diagnostics, for an important panel discussion at the 2025 Pathology Informatics Summit alongside top voices in the field of pathology informatics. This focus session will dive into: The impact of the FDA’s Final Rule on Laboratory Developed Tests (LDTs) Data governance, standardization, and access challenges for AI in pathology The urgent need for broadly sourced datasets to support the next generation of clinical AI models Panel Moderator : Ulysses Balis, MD Expert Panelists : Victor Brodsky, MD – Washington University School of Medicine, St. Louis Lisa-Jean Clifford – Gestalt Diagnostics Bruce Friedman, MD Ronald Jackups, MD, PhD – Washington University School of Medicine, St. Louis Amrom Obstfeld, MD, PhD – Children’s Hospital of Philadelphia Michelle Stoffel, MD, PhD – University of Minnesota J. Mark Tuthill, MD – Henry Ford Health System This dynamic session includes two panel discussions followed by open Q&A: The FDA’s Final Rule on LDTs The Growing Crisis of Limited AI Training Data in Pathology Why it matters : With regulatory landscapes shifting and AI innovation surging, this session offers a rare chance to hear from experts shaping the future of diagnostics, data ethics, and clinical technology adoption. Don’t miss this opportunity to learn from Lisa-Jean and fellow leaders who are building the next chapter of pathology informatics.
Spokane, Washington, April 28, 2025 – Gestalt, a leading innovator in AI-powered digital pathology solutions, announced the completion of a $7.5 million Series A financing. The round was led by Cowles Ventures, TVF Funds, Inland Imaging Investments, KickStart Funds, and prominent angel investors from the Pacific Northwest. Gestalt’s PathFlow® platform is used by leading healthcare, academic medical centers, and research organizations. Customers implement PathFlow as their preferred solution because it integrates seamlessly into their existing laboratory information systems, enabling faster, more accurate diagnoses and improving access to expert consultation, education, and research—regardless of location. "PathFlow is transforming pathology by leveraging robust digital workflows and AI algorithms to support scoring of key biomarkers. This enables organizations to accurately match patients to known therapies and generate rich datasets for research and new drug development," said Dan Roark, CEO, Gestalt. "Our technology is designed to improve patient outcomes by enabling faster, more accurate diagnoses and broadening access to clinical expertise." This new funding will facilitate broader market adoption and increased profitability. The capital will be used to expand the company’s customer base, enhance AI capabilities, and pursue FDA clearance. This comes at a critical moment, with rising cancer rates and a declining number of practicing pathologists intensifying the need for scalable, digital-first diagnostic solutions. “We are incredibly grateful for the continued support from our investors,” Roark added. “This funding allows us to expand on the solid foundation we’ve built. We’ve already streamlined how pathologists navigate fragmented systems by creating PathFlow, a unified platform for viewing pathology cases digitally and collaborating with leading experts in real-time without the need to ship specimens. Now, we’ll accelerate innovation and scale our reach to meet the growing demands of modern pathology.” Gestalt is at the forefront of a critical shift in diagnostic medicine, helping transform pathology from a manual, microscope-based process to a scalable digital solution leveraging artificial intelligence tools — like the digital transitions already seen in radiology and cardiology. The company’s platform not only improves diagnostic speed and precision which is critical for cancer patients who can wait for days to weeks or more for a diagnosis, but also unlocks AI-powered insights that enable: Biomarker scoring to support the optimization of patient-therapy matching, Image and data analysis for disease progression studies, And the interoperability that enables pathologists access to valuable aides and insights that streamline their workflows, highlight areas of positivity and reduce missed diagnoses. With this Series A funding, Gestalt remains committed to expanding its impact through the deployment of its’ PathFlow software in healthcare, making high-quality, scalable pathology solutions more accessible to clinicians and researchers worldwide. About Gestalt Gestalt Diagnostics is a Spokane-based company dedicated to revolutionizing pathology through digital solutions. Founded in 2017, Gestalt provides advanced technology, proven digital expertise, and artificial intelligence to enable pathologists to diagnose diseases faster and more efficiently. The company's PathFlow platform is at the forefront of digital pathology innovation, offering significant improvements in diagnostic accuracy and workflow efficiency. To learn more, visit www.gestaltdiagnostics.com and follow @Gestalt on LinkedIn
March 21, 2025 – Mumbai, India and Spokane, Washington – AIRA Matrix, a leading innovator in AI-driven QC solutions, and Gestalt, an industry leader in IMS and digital pathology, have formed a strategic partnership to bring AIRA Matrix’s advanced AI solution, AIRAQC, to Gestalt's PathFlow. This collaboration marks a significant step toward enhancing diagnostic precision and efficiency in laboratories worldwide. AIRAQC, powered by cutting-edge artificial intelligence, streamlines quality control processes, enabling faster and more accurate analysis in pathology workflows. By integrating AIRAQC with Gestalt's workflows, pathologists will gain access to a seamless, AI-enhanced experience designed to optimize diagnostic decision-making. "We're thrilled to partner with Gestalt to expand the reach of AIRAQC and deliver transformative AI capabilities to pathology labs," said Marco Comianos, Head of Commercial Operations - US., AIRA Matrix. "This collaboration is a testament to our shared commitment to advancing pathology through innovation." “The partnership between AIRA Matrix and Gestalt represents a continued effort to drive progress in pathology by leveraging technology to meet evolving healthcare needs. Together, our companies aim to empower laboratories with state-of-the-art tools that improve diagnostic accuracy, quality and meaningful metrics from the start of the diagnostic process” says Lisa-Jean Clifford, Gestalt COO & Chief Strategy Officer. About AIRA Matrix: Delivers artificial intelligence solutions for healthcare and life sciences applications. Our innovative products and services drive efficiency, enhance diagnostic accuracy, and provide data-driven insights from digitally scanned images. Our comprehensive AI-driven suite for drug discovery and development, streamlines pre-analytical quality control, facilitates tissue triage, and optimizes safety and efficacy assessments, accelerating breakthrough discoveries. Our healthcare portfolio offers diagnostic, prognostic, and predictive tools that facilitate risk stratification and enable personalized therapy planning, thus improving treatment outcomes., visit www.airamatrix.com. About Gestalt Diagnostics: Gestalt transforms pathology through an intelligent, configurable, vendor-neutral, and AI-driven digital workflow that provides true interoperability enabling pathologists to diagnose* diseases faster and more efficiently. Our PathFlow® solution consists of professional, education, and research modules for ease of mixing and matching the digital needs of your facility in a single solution, freeing pathologists from tedious, repetitive, and manual tasks allowing them to focus on their expertise, providing invaluable experience where it matters most. *Following the LDT process in the US. It is under CE-IVD marking for use in Europe.
March 21, 2025 – Spokane, Washington – Gestalt, a leader in AI driven digital pathology solutions, and DLS Pathology Services, a reseller and consultation company providing expert direction on digital adoption and services are excited to announce a global reseller partnership. This collaboration brings Gestalt’s acclaimed digital platform directly to pathologists and healthcare entities in Australia and other territories. This reseller agreement continues Gestalt’s expansion into other countries through the locally focused expertise and experience of DLS Pathology Services. In this arrangement, DLS will be providing the sales and first line support of Gestalt’s digital pathology capabilities, ensuring that pathologists have the ability to leverage their consultations for pathology as a service provider and support. "We are excited to join forces with DLS Pathology Services to bring our industry leading digital pathology solutions to a wider global audience," said Lisa-Jean Clifford, COO & Chief Strategy Officer, Gestalt. "This partnership enables us to combine our innovative platform with DLS's local expertise, ensuring pathologists in Australia and beyond have the tools and support they need to provide exceptional diagnostic services.” “Gestalt provides the ideal platform for providing digital pathology services. Its ability to host and stream DICOM images at low-cost, with an intuitive interface for pathologists, helps us service clients at any scale”, says Dr. Jeremy Parry, Director, DLS Pathology Services. “I have been in the digital pathology business for more than a decade and tried pretty much all the Cloud platforms out there. With its speed, user-friendly interface and innovative use of DICOM, Gestalt is the best of the lot.” For more information about this partnership and the respective solutions, please visit Gestalt at booth #934 during USCAP March 23-26, 2025. About Gestalt Gestalt Diagnostics transforms pathology through an intelligent, configurable, vendor-neutral, and AI-driven digital workflow that provides true interoperability enabling pathologists to diagnose* diseases faster and more efficiently. Our PathFlow solution consists of professional, education, and research modules for ease of mixing and matching the digital needs of your facility in a single solution, freeing pathologists from tedious, repetitive, and manual tasks, allowing them to focus on their expertise – providing invaluable experience where it matters most. About DLS Pathology Services Our mission is to support and develop local pathology services, no matter what the budget or location. Recent progress in digital technologies means that no pathology service should be limited by remote geographical location, lack of local support, limited budgets or the shortcomings of traditional glass-slide (analogue) pathology workflows. At DLS Pathology Services, we believe that every medical service, with the appropriate support, can grow and flourish to support the needs of its local community. DLS stands for Deep Learning Solutions which underlines the Company's aim of developing and utilizing deep-learning and other machine applications as much as possible for the benefit of clients. To learn more, visit www.dlspath.com . *Following the LDT process in the US. It is under CE-IVD marking for use in Europe.
